Herbert Smith Freehills advises sponsors on Antengene’s HK$2.6 billion Hong Kong IPO / 史密夫斐尔律师事务所作为联席保荐人境外律师为德琪医药26亿港元IPO提供法律服务 Herbert Smith Freehills Global law firm

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The company offers industry-leading R&D capabilities and a differentiated strategic approach to developing novel oncology therapies.

The IPO was over-subscribed more than 264 times at the Hong Kong public offering, raised over HK$2.6 billion (US$335 million), and listed on 20 November 2020.…

This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.

Visit the original:

Comments are closed.